Solid TumoursPhase 1NCT00497679
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
A Phase 1 study testing AZD1152 in people with Solid Tumours, run by AstraZeneca at 3 sites in United Kingdom.
Trial summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Solid Tumours
- What is being tested?
- AZD1152
- Type of treatment
- Injection or infusion
- How many people
- 45 participants
- Where
- 3 sitesUnited Kingdom
- Study dates
- Aug 2006to Jul 2007
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histological or cytological confirmation of a solid, malignant tumour
Who cannot join
- Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug
- Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
- Recent major surgery within 4 weeks prior to entry to the study
Trial locations and contacts
3 sites in 1 country.
United Kingdom3 sites
Research Site
Manchester
Research Site
Newcastle
Research Site
Oxford
About this study
Official title: A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
- Conditions
- Solid Tumours
- Being tested
- AZD1152
- Keywords
- advanced solid tumours
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AZD1152Drug
7-day continuous intravenous infusion
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Tolerability
Measured: Assessed at each visit
Secondary outcomes (3)
Pharmacokinetics
Measured: Assessed at predetermined timepoints after dose administration
Effect on biomarkers
Measured: Assessed after treatment
Anti-tumor activity
Measured: Assessed at the end of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2007 (estimated)
- Study startAug 2006
- Study completionJul 2007
Why it stopped: Study is now terminated due to technical difficulties with administration of study drug in this patient population with this schedule
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid TumoursStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- David Kerr, MD, Principal investigator, University of Oxford
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00497679
- Sponsor's protocol ID
- D1531C00003
- Other IDs
- EudraCT: 2005-004244-31
- Status last verified
- May 2009
- First submitted
- 5 Jul 2007
- Last updated
- 14 May 2009
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies
- ClinicalTrials.gov ID
- NCT00497679
- Acronym / sponsor ID
- D1531C00003
- Conditions
- Solid Tumours
- Keywords
- advanced solid tumours
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Study is now terminated due to technical difficulties with administration of study drug in this patient population with this schedule
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Aug 2006
- Study completion
- Jul 2007 (actual)
- First posted
- 9 Jul 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Histological or cytological confirmation of a solid, malignant tumour
Key exclusion criteria (3 listed)
- Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug
- Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
- Recent major surgery within 4 weeks prior to entry to the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AZD11527-day continuous intravenous infusion | Drug | – |
Primary outcome
Safety and Tolerability
Time frame: Assessed at each visit
3 secondary outcomes
Pharmacokinetics
Time frame: Assessed at predetermined timepoints after dose administration
Effect on biomarkers
Time frame: Assessed after treatment
Anti-tumor activity
Time frame: Assessed at the end of treatment
Results and safety
The study was stopped early (reason given: Study is now terminated due to technical difficulties with administration of study drug in this patient population with this schedule). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2009.
Related trials for Solid Tumours
Enrolling by invitationObservational study
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Pediatric Cancers, Hematologic Malignancies
RecruitingPhase 4
Dabrafenib and/or Trametinib Rollover Study
Melanoma, Non Small Cell Lung Cancer
Active, not recruitingPhase 2
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors, NSCLC
RecruitingObservational study
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Kerr, MD principal investigator
University of Oxford
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing AZD1152 in people with Solid Tumours, run by AstraZeneca at 3 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 14 May 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Study is now terminated due to technical difficulties with administration of study drug in this patient population with this schedule). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Tolerability (time frame: Assessed at each visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2009; AzTrials last refreshed its copy on 4 Nov 2026.